Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
John Meyne, Senior Vice President and President of North America, will retire effective December 31, 2026. Paul Shaw, currently the segment's SVP of Operations and a 25-year veteran of the company, has been appointed to succeed him effective January 1, 2027.
International Battery Metals Ltd. reported a net income of $2.14 million for the six months ended September 30, 2026, primarily driven by a $7.93 million non-cash gain from the change in fair value of warrant liabilities. Despite the net profit, the company experienced an operating loss of $5.78 million and negative cash flow from operations as it continues to market its modular direct lithium extraction (MDLE) technology.
Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.
International Battery Metals reported Q2 fiscal 2027 results, including a net income of $2.2 million driven by a $5.0 million gain in the fair value of warrant liabilities. The company announced plans to build a compact, transportable pilot plant to provide field data for North American resource owners and expects to secure a $12.0 million bridge loan from its largest investor.
Term
Q2 2027
“We continue to evaluate opportunities across North America, including through an active laboratory testing program. Our ongoing discussions with North American resource owners have made clear that one of their biggest challenges is they need field data from their own resources before making investment decisions. To meet that need, we have begun engineering a compact pilot plant that can be deployed at sites quickly, and at a lower cost than our existing demonstration plant.”
Our Bond, Inc. entered into agreements to convert Series B Preferred Stock with a total stated value of $13.26 million into 6,532,640 shares of common stock at a conversion price of $2.03 per share. The transaction reduces the company's total outstanding preferred liquidation preference from approximately $20.9 million to $7.6 million. Participating holders, including the CEO and an independent director, are subject to a six-month lock-up period followed by volume-based resale restrictions.
Adagio Medical Holdings, Inc. reported a significant decrease in cash and cash equivalents from $17.1 million at the end of 2025 to $3.1 million as of September 30, 2026. The company highlighted substantial risks regarding its ability to continue as a going concern and is exploring strategic alternatives to maximize stockholder value.
Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.
“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”
Accelevation Holdings Corp. reported Q3 2026 financial results with revenue growing 66% year-over-year to $202.2 million and a significant bookings increase of 364%. The company also issued an amendment to correct errors in its original earnings release regarding SG&A margins and Adjusted SG&A calculations.
“At Accelevation, we design, manufacture, and install mission-critical infrastructure for customers who rely on our speed and certainty of delivery, and our third quarter results reflect the strength of our operating model and underlying markets.”
Michael Rubiera, Co-Founder and Chief Executive Officer
“We delivered strong growth, profitability, and cash generation in the quarter. Revenue increased more than 60%, bookings grew more than 350%, backlog rose to approximately $1.7 billion, and Adjusted EBITDA margins approached 19% following a weaker first half of the year.”
Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.
Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.
Term
Q3 2026
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”
Todd Usen, Chief Executive Officer of Adagio Medical
“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”
Todd Usen, Chief Executive Officer of Adagio Medical
Suncrete, Inc. reported a significant revenue increase to $300.0 million for the nine months ended September 30, 2026, compared to $130.8 million in the prior year, driven by acquisition activity. However, the company realized a net loss attributable to common stockholders of $55.0 million for the period, primarily due to higher interest expenses and substantial acquisition-related costs.
Montauk Renewables reported total operating revenues of $150.6 million for the nine months ended September 30, 2026, up from $133.0 million in the prior year. The company achieved a net income of $2.37 million for the period, recovering from a net loss of $0.75 million in 2025, despite an operating loss of $2.6 million driven by higher operating and maintenance expenses.
Abeona Therapeutics Insider Faith L. Charles Buys $34.3K of Stock
Faith L. Charles bought 15,000 shares of Abeona Therapeutics Inc. at $2.29 a share, worth $34.3K in total on Nov 13, 2026. Shares held after the trade: 191,407 (+8.5%).
Digimarc entered into a cooperation agreement with its largest shareholder, Ocho Investments LLC, resulting in a significant board refreshment. The company appointed three new directors (Andris Upitis, Kevin McConnell, and Amy O’Keefe) while announcing the upcoming retirement of four current directors by year-end 2026.
Nuvera Communications reported total operating revenues of $17.4 million for the third quarter of 2026, a slight decrease from $18.0 million in the prior year, primarily due to lower A-CAM/FUSF and video service revenues. Despite the revenue dip, operating income improved to $2.66 million as the company reduced operating expenses, though it ultimately recorded a net loss of $176,261 for the quarter due to high interest expenses.
TerraVolt Holdings, Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2026, compared to a $5.7 million loss in the prior year period. The company is currently pre-revenue and focused on financing and constructing proposed data center operations, with total assets increasing to $13.55 million primarily due to new restricted cash and other assets.
ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.
Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.
“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”
Jeet Mahal, President and Chief Executive Officer of Jasper
“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Jeet Mahal, President and Chief Executive Officer of Jasper
Super League Enterprise, Inc. announced the purchase of eight Bitcoin at an average price of approximately $68,948.90 per coin. The acquisition is part of the company's strategy to explore Bitcoin as a treasury reserve asset alongside its existing cash and cash equivalents.
Venu Holding Corp reported its Q3 2026 financial results, highlighting a 59% increase in total assets to $587.6 million since year-end 2025. The company is transitioning from a construction phase to an operational phase with the upcoming opening of the Regent Bank Amphitheater on New Year's Eve and the Sunset Amphitheater McKinney in Q1 2027.
Term
Q3 2026
“Next quarter, VENU moves from building to operating. With two venues coming online, we expect to see a meaningful step up in ticketing, food and beverage, and sponsorship revenue in fiscal 2027. Content drives all of it, and we already have more than 110 holds on the calendar across our portfolio.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
“What you see in our results today is the cost of bringing more than $600 million in assets online by mid-2027, and we continue to expect to be in a position to provide financial guidance in the middle of next year.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
Outdoor Holding Company reported its fiscal second quarter 2027 results, featuring a 14.6% revenue increase to $13.7 million and net income growth to $2.3 million. The company outperformed the broader firearms market with a 10.3% increase in Gross Merchandise Value (GMV) and a 25 basis point increase in take rate to 6.59%.
The Children’s Place, Inc. and certain subsidiaries filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company secured $282 million in debtor-in-possession (DIP) financing, consisting of a $166 million asset-based revolving facility and a $116 million term loan facility to fund operations and case administration. The financing includes the refinancing of prepetition debt and is subject to court-approved budget and variance compliance.
Strategy Inc reported that it sold 2,087,040 shares of Class A Common Stock (MSTR) under its at-the-market offering program between November 9 and November 15, 2026, generating net proceeds of $244.7 million. The company utilized $33.4 million of these proceeds to purchase 485 additional bitcoins and $206.3 million to fund repurchases of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC).
Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.
Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.
Brian Halligan, CEO, bought 22,985 shares of Hubspot Inc at $217.44 a share, worth $5M in total on Nov 13, 2026. Shares held after the trade: 82,485 (+38.6%).
Vivani Medical Insider Gregg Williams Buys $47.8K of Stock
Gregg Williams bought 48,100 shares of Vivani Medical, Inc. at $0.993 a share, worth $47.8K in total on Nov 13, 2026. Shares held after the trade: 36,960,836 (+0.1%).
Optimum Communications $102M Debt Financing with ad hoc group of debtholders
Optimum Communications' subsidiary CSC Holdings elected to skip $102.5 million in interest payments due on three series of senior notes, entering a 30-day grace period to avoid default. The company is utilizing the grace period to maximize flexibility during ongoing negotiations with an ad hoc group of debtholders regarding a potential restructuring of its $22 billion debt load. Operations continue as normal, and the non-payment does not currently trigger cross-defaults under other indebtedness.
Strive, Inc. provided a weekly update on its treasury holdings, disclosing the purchase of 251 bitcoin for approximately $17.5 million between November 7 and November 13, 2026. As of November 13, the company held 43,404 bitcoin and $465.3 million in cash and cash equivalents. The company also reported raising $10.02 million in gross proceeds through the sale of 104,478 shares of its 15.00% Series A Perpetual SATS Preferred Stock under its at-the-market offering program.
Sami Totah, Director, sold 6,000 shares of Radcom Ltd at $11.00 a share, worth $66K in total on Nov 12, 2026. Shares held after the trade: 24,175 (-19.9%).